Showing results (101-110 of 165) with videos related to
Sort By:
Pageof 17
Journal of Virology|December 14, 2007
Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion proteinBerend Jan Bosch, John W A Rossen, Willem Bartelink, et al.Plos One|August 17, 2013
A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particlesAlan Rigter, Ivy Widjaja, Hanneke Versantvoort, et al.Journal of Virology|March 29, 2013
Substitutions T200A and E227A in the hemagglutinin of pandemic 2009 influenza A virus increase lethality but decrease transmissionCarles Martínez-Romero, Erik de Vries, Alan Belicha-Villanueva, et al.Proceedings of the National Academy of Sciences of the United States of America|January 21, 2016
Enterovirus D68 receptor requirements unveiled by haploid geneticsJim Baggen, Hendrik Jan Thibaut, Jacqueline Staring, et al.Plos One|January 31, 2017
Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of AgeJop Jans, Oliver Wicht, Ivy Widjaja, et al.Plos Pathogens|July 25, 2024
Unraveling dynamics of paramyxovirus-receptor interactions using nanoparticles displaying hemagglutinin-neuraminidaseXuesheng Wu, Maite Goebbels, Oliver Debski-Antoniak, et al.Journal of Virology|November 24, 2017
Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of InfluenzaE R Job, M Schotsaert, L I Ibañez, et al.Journal of Virology|August 12, 2016
Identification of Residues That Affect Oligomerization and/or Enzymatic Activity of Influenza Virus H5N1 Neuraminidase ProteinsMeiling Dai, Hongbo Guo, Jos C F M Dortmans, et al.Nature Communications|July 13, 2022
Human-type sialic acid receptors contribute to avian influenza A virus binding and entry by hetero-multivalent interactionsMengying Liu, Liane Z X Huang, Anthony A Smits, et al.Vaccine|July 29, 2020
First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trialPauline Verdijk, Johan L van der Plas, Emilie M J van Brummelen, et al.Pageof 17